Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Stock analysts at Oppenheimer dropped their Q2 2019 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a note issued to investors on Wednesday, July 17th. Oppenheimer analyst E. Rajavelu now forecasts that the company will post earnings of $0.59 per share for the quarter, down from their prior forecast of $0.61. Oppenheimer has a “Buy” rating and a $12.00 price target on the stock. Oppenheimer also issued estimates for Teva Pharmaceutical Industries’ FY2019 earnings at $2.32 EPS and FY2020 earnings at $2.35 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. The business had revenue of $4.30 billion for the quarter, compared to the consensus estimate of $4.38 billion. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business’s revenue for the quarter was down 15.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.94 EPS.

Several other research analysts also recently weighed in on TEVA. Zacks Investment Research downgraded shares of Guaranty Federal Bancshares from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. Barclays reissued a “hold” rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Maxim Group reissued a “hold” rating on shares of Arlington Asset Investment in a research report on Thursday, May 2nd. Wells Fargo & Co set a $17.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Tuesday, May 28th. Finally, Royal Bank of Canada set a $60.00 price objective on shares of Masonite International and gave the company a “buy” rating in a research report on Friday, May 3rd. Six equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $15.39.

Teva Pharmaceutical Industries stock opened at $7.91 on Friday. The stock has a 50 day moving average price of $8.87. The stock has a market capitalization of $7.96 billion, a P/E ratio of 2.83, a P/E/G ratio of 0.94 and a beta of 1.62. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96. Teva Pharmaceutical Industries has a fifty-two week low of $7.66 and a fifty-two week high of $25.96.

A number of large investors have recently added to or reduced their stakes in TEVA. G&S Capital LLC increased its holdings in Teva Pharmaceutical Industries by 99.4% in the 2nd quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock valued at $37,000 after buying an additional 2,000 shares during the period. Lindbrook Capital LLC increased its holdings in Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after buying an additional 945 shares during the period. NEXT Financial Group Inc increased its holdings in Teva Pharmaceutical Industries by 384.8% in the 2nd quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock valued at $39,000 after buying an additional 3,394 shares during the period. Cullen Frost Bankers Inc. bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $40,000. Finally, Edgemoor Investment Advisors Inc. bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $54,000. Hedge funds and other institutional investors own 65.05% of the company’s stock.

In other news, Director Sol J. Barer acquired 111,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, June 3rd. The stock was acquired at an average cost of $8.98 per share, for a total transaction of $996,780.00. Following the completion of the purchase, the director now owns 115,942 shares of the company’s stock, valued at $1,041,159.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the completion of the sale, the vice president now owns 49,659 shares of the company’s stock, valued at $567,105.78. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: What is the quiet period?

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.